Chemical Reprogramming of Skin Fibroblasts Into Oligodendrocytes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating oligodendrocyte-lineage cells (OLGs) are labor-intensive, costly, and face challenges such as the risk of teratoma formation and low efficiency, particularly when using human embryonic stem cells or rodent cells, making it difficult to obtain sufficient quantities for cell therapy in demyelinating diseases.

Innovation Solution

Skin cells, such as fibroblasts, are reprogrammed into induced OLGs using a chemical inducer comprising a Rho-associated protein kinase (ROCK) inhibitor, along with auxiliary agents like histone deacetylase (HDAC) inhibitors, cyclin-dependent kinase (CDK) inhibitors, and cyclic adenosine monophosphate (cAMP) activators, without the need for gene modification, enabling efficient conversion to OLGs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If human embryonic stem cells or rodent cells are used to generate oligodendrocyte-lineage cells, then cell therapy can be provided, but the process is labor-intensive, costly, and has low efficiency with risks of teratoma formation

Engineering Contradiction:

Improvesafety of cell therapyVSAvoidconversion efficiency to OLGs

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The invention changes the chemical and biological parameters of cell reprogramming by using a specific cocktail of small molecule compounds (ROCK inhibitor, HDAC inhibitor, CDK inhibitor, and cAMP activator) instead of traditional transcription factor overexpression or embryonic stem cell differentiation protocols. This parameter change enables direct reprogramming of skin fibroblasts into oligodendrocyte-lineage cells with high efficiency and safety, avoiding teratoma formation while maintaining high conversion rates

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention replaces the complex mechanical and biological system of embryonic stem cell culture and differentiation with a simplified chemical reprogramming system using small molecule compounds. This substitution eliminates the need for labor-intensive manual operations, reduces costs, and increases productivity by enabling straightforward chemical treatment of skin cells to generate therapeutic oligodendrocyte-lineage cells

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Quantity of substance

If traditional methods are used to generate sufficient quantities of OLGs for cell therapy, then treatment can be provided, but the process is labor-intensive and costly

Engineering Contradiction:

Improvequantity of OLGs producedVSAvoidsimplicity of production process

Core Design Contradiction:

Quantity of substanceVSEase of manufacture

Solution Approach 1:

The invention enables skin fibroblasts to self-reprogram into oligodendrocyte-lineage cells through direct chemical treatment without requiring complex external manipulation, specialized cell culture conditions, or multiple differentiation stages. The cells perform the conversion themselves when exposed to the chemical cocktail, dramatically simplifying the manufacturing process while enabling large-scale production of therapeutic cells

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The invention extracts and isolates the essential reprogramming function into a defined chemical cocktail of small molecules, separating it from the complex embryonic stem cell systems. This extraction allows the reprogramming capability to be applied directly to skin fibroblasts in a simple, scalable manner, increasing both quantity produced and ease of manufacture

Inventive Principle:

Principle #2Taking out (Extraction)

3Adaptability or versatility

If gene modification is used to reprogram cells into OLGs, then conversion can occur, but the process becomes complex and less safe

Engineering Contradiction:

Improveability to reprogram cellsVSAvoidcomplexity of reprogramming method

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The invention replaces gene modification techniques (viral transduction, plasmid transfection, CRISPR editing) with a purely chemical reprogramming approach using small molecule compounds. This substitution maintains the ability to reprogram cells into oligodendrocyte-lineage cells while dramatically reducing complexity and eliminating safety concerns associated with genetic modification, including insertional mutagenesis and off-target effects

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS12553028B2Method to generate induced oligodendrocyte-lineage cells and treatment using such cells

Publication Date: 2026.02.17 ACAD SINICA

AI summary

The present invention generally relates to a method for generating induced oligodendrocyte-lineage cells (induced OLGs) and treatment using such cells. The induced OLGs are useful in cell therapy, in particular for demyelinating diseases.